Archive

Filter

Merck recently unloaded its portfolio of drugs that will soon lose their patent protection, freeing up capital to invest in research and development. Read More

This month’s Personal Finance options recommendation includes two strategies, selling a covered call and selling a naked put on Texas Instruments (Nasdaq: TXN) as described below. If you already own shares of Texas Instruments, then you should consider selling a covered call against that stock position, but if you do… Read More

AbbVie is the least expensive of the world’s 10 largest pharmaceutical companies despite its success in extending Humira’s patent protection for several years. I'm raising our buy limit to $125. Read More